Paolo F. Caimi

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 22 papers. Top paper: “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study”.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

The Lancet(2020)10.1016/s0140-6736(20)31187-9

N/A

11.9DataRank · unranked

1804 citations

Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera +95 more

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Annals of Oncology(2021)10.1016/j.annonc.2021.02.024

N/A

6.8DataRank · unranked

328 citations

Ali Raza Khaki, Trisha M. Wise‐Draper, Benjamin French, Conor Hennessy, Chih–Yuan Hsu +95 more

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

The Lancet Haematology(2021)10.1016/s2352-3026(21)00103-4

N/A

2.5DataRank · unranked

86 citations

Graham P. Collins, Paolo F. Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies +13 more

A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Blood Advances(2024)10.1182/bloodadvances.2023011514

N/A

1.2DataRank · unranked

33 citations

Ronald Sobecks, Christina Cho, Pingfu Fu, Seunghee Margevicius, Jiasheng Wang +16 more

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djz245

N/A

0.817DataRank · unranked

231 citations

Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton +35 more

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool

Journal of Geriatric Oncology(2021)10.1016/j.jgo.2021.10.003

N/A

0.736DataRank · unranked

24 citations

Hongli Li, Anne Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh +9 more

Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1586

N/A

0.673DataRank · unranked

88 citations

Changjin Hong, Robert Schauner, Boro Dropulić, Paolo F. Caimi, Marcos de Lima +6 more

Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study

Haematologica(2021)10.3324/haematol.2020.270876

N/A

0.571DataRank · unranked

44 citations

Andrew M. Evens, Alexey V. Danilov, Stephen D. Smith, Deepa Jagadeesh, Lori A. Leslie +52 more

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Cancer Cell(2020)10.1016/j.ccell.2020.10.022

N/A

0.529DataRank · unranked

33 citations

David M. Aboulafia, Melissa Accordino, Jared D. Acoba, Manmeet S. Ahluwalia, Syed A. Ahmad +95 more

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7503

N/A

0.449DataRank · unranked

19 citations

Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir Parekh, David T. Yang +15 more

Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States

JAMA Network Open(2022)10.1001/jamanetworkopen.2021.42046

N/A

0.373DataRank · unranked

11 citations

Tianyi Sun, David D. Chism, Narjust Duma, Julie Fu, Na Tosha Gatson +87 more

Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience

Journal of Computer Assisted Tomography(2020)10.1097/rct.0000000000001043

N/A

0.292DataRank · unranked

6 citations

Ezgi Guler, Daniel A. Smith, Sree Harsha Tirumani, Christopher Hoimes, Paolo F. Caimi +2 more

BEAM versus pharmacokinetics‐directed BuCyVP16 conditioning for patients with peripheral T‐cell lymphoma undergoing high‐dose therapy with autologous hematopoietic cell transplantation

American Journal of Hematology(2024)10.1002/ajh.27291

N/A

0.104DataRank · unranked

1 citations

Agrima Mian, Samantha Brown, Sean M. Devlin, Paolo F. Caimi, Stephanie Chinapen +14 more

Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients

JACC CardioOncology(2023)10.1016/j.jaccao.2023.02.001

N/A

0DataRank · unranked

21 citations

Wyatt P. Bensken, Long Vu, Weichuan Dong, Siran M. Koroukian, Paolo F. Caimi +1 more

Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells

Cells(2023)10.3390/cells12141880

N/A

0DataRank · unranked

8 citations

Meixian Huang, Mi-Ae Lyu, Joseph D. Khoury, Sairah Ahmed, Krina K. Patel +8 more

PHASE II/III STUDY OF R‐MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS

Hematological Oncology(2023)10.1002/hon.3166_ot27

N/A

0DataRank · unranked

0 citations

H. Li, Anne Beaven, Paolo F. Caimi, Leandro Cerchietti, Rebecca L. Olin +9 more

Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.4304

N/A

0DataRank · unranked

72 citations

Sonya Reid, Benjamin French, Cassandra Hennessy, Clara Hwang, Na Tosha Gatson +95 more

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Blood(2021)10.1182/blood.2021012888

N/A

0DataRank · unranked

95 citations

Daniel Reed, Ashley McCook, Jeremy Sen, Christian Barlow, Mary‐Kate Malecek +48 more

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States

Blood Neoplasia(2025)10.1016/j.bneo.2025.100156

N/A

0DataRank · unranked

1 citations

Weichuan Dong, Aaron T. Gerds, Hetty E. Carraway, Abhay Singh, Anjali S. Advani +9 more

Validation of Pre-Treatment Modified Easix Score As a Predictor of Cytokine Release Syndrome Related to Anti CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Transplantation and Cellular Therapy(2022)10.1016/s2666-6367(22)00337-2

N/A

0DataRank · unranked

0 citations

Wei Wei, Allison M. Winter, Jack Khouri, Deepa Jagadeesh, Faiz Anwer +9 more

Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis

Blood Advances(2024)10.1182/bloodadvances.2024013688

N/A

0DataRank · unranked

40 citations

Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder, Joeseph Maakaron +12 more

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood(2023)10.1182/blood.2023021274

N/A

0DataRank · unranked

47 citations

Nicholas Lambert, Paolo F. Caimi, Mwanasha H. Merrill, Priyanka Pullarkat, Richard Godby +19 more